“…A number of HDAC inhibitors are in clinical development as anticancer agents (Xu et al, 2007), and one of them, suberoylanilide hydroxamic acid, has recently been approved for the treatment of advanced cutaneous T cell lymphoma (Marks, 2007). While most of the HDACs are localized in the nucleus, HDAC6 is a cytoplasmic protein associated with the cytoskeleton and involved in cytoskeleton-related activities (Boyault et al, 2007;Valenzuela-Fernández et al, 2008). There is a growing body of evidence showing that HDAC6 functions at the intersection of the cytoskeleton and cell signaling to regulate cell motility, cell adhesion, and cell-cell interactions (Boyault et al, 2007;Valenzuela-Fernández et al, 2008).…”